SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ATIS is on the move!
ATIS 0.1000-47.4%Apr 14 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Marshall Teitelbaum who wrote (1283)1/14/1998 5:35:00 PM
From: Rick Strange  Read Replies (1) of 2205
 
Smith & Nephew is expanding the fifty-fifty joint venture with ATIS for worldwide development and marketing of Dermagraft for venous ulcers and pressure sores and the marketing of Dermagraft-TC outside the U.S.
Deal calls for $35 million within the next twelve months inclusing $20 million investment in stock. Payments to ATIS including the diabetic foot ulcer indication, can potentially total up to $181 million, subject to achievement of certain milestones.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News